Erratum: EGFP-EGF1-Conjugated PLGA Nanoparticles for Targeted Delivery of siRNA into Injured Brain Microvascular Endothelial Cells for Efficient RNA Interference (PLoS ONE (2013) 8:4 (e60860) DOI: 10.1371/journal.pone.0060860);EGFP-EGF1-Conjugated PLGA Nanoparticles for Targeted Delivery of siRNA into Injured Brain Microvascular Endothelial Cells for Efficient RNA Interference

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chen, Chen ^a,b   Mei, Heng ^a,b   Shi, Wei ^a,b   Deng, Jun ^a,b   Zhang, Bo ^a,b   Guo, Tao ^a,b   Wang, Huafang ^a,b   Hu, Yu ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; EGFP EGF1 CONJUGATED POLYGLACTIN NANOPARTICLE; SMALL INTERFERING RNA; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; GENE DELIVERY SYSTEM; GENE SILENCING; GENETIC TRANSFECTION; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE;

EID: 84876037756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0303121     Document Type: Erratum

References (37)

1. Brown RC, Morris AP, O'Neil RG, (2007) Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 1130: 17-30.
2. Correale J, Villa A, (2009) Cellular elements of the blood-brain barrier. Neurochem Res 34: 2067-2077.
3. Mukerjee A, Shankardas J, Ranjan AP, Vishwanatha JK, (2011) Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells. Nanotechnology 22: 445101.
4. Mackman N, (2009) The many faces of tissue factor. Journal of Thrombosis and Haemostasis 7: 136-139.
5. Mackman N, (2009) The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 108: 1447-1452.
6. Mackman N, (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24: 1015-1022.
7. Mackman N, (2009) The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 108: 1447-1452.
8. Kim I, Oh JL, Ryu YS, So JN, Sessa WC, et al. (2002) Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 16: 126-128.
9. Steffel J, Luscher TF, Tanner FC, (2006) Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation 113: 722-731.
10. Lares MR, Rossi JJ, Ouellet DL, (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28: 570-579.
11. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
12. Castanotto D, Rossi JJ, (2009) The promises and pitfalls of RNA-interference-based therapeutics. Nature 457: 426-433.
13. Whitehead KA, Langer R, Anderson DG, (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
14. Jensen DK, Jensen LB, Koocheki S, Bengtson L, Cun D, et al. (2011) Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release.
15. Jensen DM, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, et al. (2010) Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release 142: 138-145.
16. Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, et al. (2011) High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. Eur J Pharm Biopharm 77: 26-35.
17. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.
18. May H, Hu Y, Zhang YH, Wang HF, Fang J, et al. (2008) [Expression of fusion protein encoding EGFP-EGF1 of rat coagulation factor VII and its binding function]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16: 181-184.
19. Shi W, Mei H, Deng J, Chen C, Wang H, et al. (2012) A tissue factor targeted nanomedical system for thrombi-specific drug delivery. Biomaterials 33: 7643-7654.
20. Szabo CA, Deli MA, Ngo TK, Joo F, (1997) Production of pure primary rat cerebral endothelial cell culture: a comparison of different methods. Neurobiology (Bp) 5: 1-16.
21. Perriere N, Demeuse P, Garcia E, Regina A, Debray M, et al. (2005) Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem 93: 279-289.
22. Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, et al. (2009) A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 54: 253-263.
23. Bierhaus A, Zhang Y, Deng Y, Mackman N, Quehenberger P, et al. (1995) Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J Biol Chem 270: 26419-26432.
24. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, et al. (2005) Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 107: 428-448.
25. Cun D, Foged C, Yang M, Frokjaer S, Nielsen HM, (2010) Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm 390: 70-75.
26. Patil Y, Panyam J, (2009) Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm 367: 195-203.
27. Rak J, Milsom C, Magnus N, Yu J, (2009) Tissue factor in tumour progression. Best Pract Res Clin Haematol 22: 71-83.
28. Bluff JE, Amarzguioui M, Slattery J, Reed MW, Brown NJ, et al. (2011) Anti-tissue factor short hairpin RNA inhibits breast cancer growth in vivo. Breast Cancer Res Treat 128: 691-701.
29. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM, (2012) Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33: 583-591.
30. Bertram JP, Williams CA, Robinson R, Segal SS, Flynn NT, et al. (2009) Intravenous hemostat: nanotechnology to halt bleeding. Sci Transl Med 1: 11ra22.
31. Fahmy TM, Samstein RM, Harness CC, Mark Saltzman W, (2005) Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 26: 5727-5736.
32. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, et al. (2001) Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18: 1157-1166.
33. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
34. Rao LV, Kothari H, Pendurthi UR, (2012) Tissue Factor encryption and decryption: Facts and controversies. Thromb Res 129Suppl 2: S13-17.
35. Potente M, Gerhardt H, Carmeliet P, (2011) Basic and therapeutic aspects of angiogenesis. Cell 146: 873-887.
36. Perrot-Applanat M, Vacher S, Toullec A, Pelaez I, Velasco G, et al. (2011) Similar NF-kappaB gene signatures in TNF-alpha treated human endothelial cells and breast tumor biopsies. PLoS One 6: e21589.
37. Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, et al. (2006) Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation 114: 1512-1521.